Clayton Syndergaard, DO
Obstetrics & Gynecology · Vernal, UTNPI 1134106784
Payments from drug & device makers
Across 140 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$639
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$371
- Teva Pharmaceuticals USA, Inc.$314
- Hologic Sales And Service, LLC$124
- Alkermes, Inc.$118
- plus $335 from 9 others
What the payments were for
- Food & beverage$2,79695%
- Education$1585%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $1,053 |
| Neurocrine Biosciences, Inc. | 29 | $639 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $371 |
| Teva Pharmaceuticals USA, Inc. | 14 | $314 |
| Hologic Sales And Service, LLC | 5 | $124 |
| Alkermes, Inc. | 7 | $118 |
| Lundbeck LLC | 3 | $73 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Indivior Inc. | 3 | $56 |
| Johnson & Johnson | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 1 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Coopersurgical, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,954 in reported general payments places this provider in the 75th percentile of 294 obstetrics & gynecology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 80 | $262,986 |
| IngrezzaValbenazine Tosylate | 33 | $246,053 |
| VraylarCariprazine Hcl | 103 | $163,350 |
| AustedoDeutetrabenazine | 13 | $93,651 |
| AristadaAripiprazole Lauroxil | 24 | $62,245 |
| PerserisRisperidone | 17 | $38,741 |
| RexultiBrexpiprazole | 19 | $30,362 |
| Lurasidone Hcl | 49 | $25,139 |
| Asenapine Maleate | 101 | $19,516 |
| Aripiprazole | 201 | $16,222 |
| Clozapine | 134 | $9,948 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $7,780 |
| Ziprasidone Hcl | 70 | $7,501 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $7,418 |
| Bupropion XlBupropion Hcl | 147 | $4,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $38 | $262,98680 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $639 | $246,05333 claims |
| AbbVieVraylar | $1,053 | $163,350103 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $314 | $93,65113 claims |
| Alkermes, Inc.Aristada | $118 | $62,24524 claims |
| Indivior Inc.Perseris, Suboxone | $56 | $46,15931 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $34 | $30,36219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 294 obstetrics & gynecology providers in Utah.
Other obstetrics & gynecology in Vernal
- David TurokSalt Lake City$3.4M
- Lori GawronSalt Lake City$2.5M
- Michael TwedeDraper$1.2M
- Alan RappleyeSalt Lake City$805K
- David YoungPleasant Grove$387K
- David BranchSalt Lake City$288K
- Steven JohnsonLayton$131K
- Scott JacobProvo$128K
- Mark StowersBountiful$121K
- Christopher HutchisonRiverton$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.